Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statement Detail (Tables)

v2.4.0.6
Condensed Consolidated Financial Statement Detail (Tables)
9 Months Ended
Sep. 30, 2012
Condensed Consolidated Financial Statement Detail [Abstract]  
Outstanding securities considered anti-dilutive
Potentially dilutive securities are excluded from the calculation of loss per share if their inclusion is anti-dilutive. The following table shows the total outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share (in thousands):

   
Three Months Ended September 30,
   
Nine Months Ended September 30,
 
   
2012
   
2011
   
2012
   
2011
 
Common stock options and restricted stock units
    5,730       4,036       5,788       3,837  
Convertible preferred stock
    -       -       -       90  
Warrants for common stock
    16,626       1,608       12,942       1,608  
Total
    22,356       5,644       18,730       5,535  
Accrued liabilities
Accrued liabilities consisted of the following at September 30, 2012 and December 31, 2011 (in thousands):

   
September 30,
2012
   
December 31,
2011
 
Accrued management incentive compensation
  $ 2,821     $ 4,096  
Accrued payroll and other benefits
    2,510       3,007  
Accrued clinical trial costs
    3,940       140  
Accrued severance payments
    642       1,207  
Other
    1,754       1,562  
Total
  $ 11,667     $ 10,012